Form 10-Q · Quarterly report
Edwards Lifesciences 10-Q, filed Nov 4, 2026
- Filed
- CIK
- 0001099800
- Accession no.
- 0001099800-26-000054
Summary
Edwards Lifesciences reported net sales of $5.105 billion for the first nine months of 2026, up 13.5% from a year earlier, driven by TAVR and TMTT products. It also disclosed the February 2026 acquisition of Autus Valve Technologies, a September 2026 CMS expansion of Medicare TAVR coverage, and several FDA and CE Mark approvals for heart-valve devices.
Key points
- Third-quarter net sales were $1.716 billion, up 10.5% year over year; TMTT sales rose 47.7% to $583.2 million in the first nine months, while TAVR rose 11.1% to $3.697 billion.
- Edwards acquired Autus Valve Technologies in February 2026 for $128.9 million plus up to $132.5 million in contingent consideration tied to regulatory and sales milestones.
- The Centers for Medicare & Medicaid Services updated its National Coverage Determination for TAVR in September 2026, expanding coverage to certain asymptomatic severe aortic stenosis patients and reducing restrictions for symptomatic patients.
- Edwards received FDA approval in 2026 for devices including TRIFORMIS RESILIA, AUTUS Size-Adjustable Valve, PASCAL Precision, and PASCAL Ace with Capture Clarity, and CE Mark for SAPIEN M3 RESILIA and EVOQUE trans-jugular access.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management's Discussion Overview The following discussion and analysis contains forward-looking statements within the meaning of the federal securities laws and should be read in conjunction with the disclosures we make concerning risks and other factors that may affect our business and operating results. See “Note Regarding Forward-Looking Statements” preceding Part I, Item 1 in this Quarterly Report on Form 10-Q. We are the leading global structural heart disease innovation company, driven by a passion to improve patient lives. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.